FRANCESCA DEL SORBO

Dr. FRANCESCA DEL SORBO

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in The Lancet Neurology
Verified
Journal Article
Open access
GWGregor K Wenning
Gregor K Wenning
FGFelix Geser
Felix Geser
FKFlorian Krismer
Florian Krismer
KSKlaus Seppi
Klaus Seppi
SDSusanne Duerr
Susanne Duerr
WPWerner Poewe
Werner Poewe
Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations. Here we present the final analysis of a prospective multicentre study by the European MSA Study Group to investigate the natural history of MSA. Patients with a clinical diagnosis of MSA were recruited and followed up clinically for 2 years. Vital status was ascertained 2 years after study completion. Disease progression was assessed using the unified MSA rating scale (UMSARS), a disease-specific questionnaire that enables the semiquantitative rating of autonomic and motor impairment in patients with MSA. Additional rating methods were applied to grade global disease severity, autonomic symptoms, and quality of life. Survival was calculated using a Kaplan-Meier analysis and predictors were identified in a Cox regression model. Group differences were analysed by parametric tests and non-parametric tests as appropriate. Sample size estimates were calculated using a paired two-group t test. 141 patients with moderately severe disease fulfilled the consensus criteria for MSA. Mean age at symptom onset was 56·2 (SD 8·4) years. Median survival from symptom onset as determined by Kaplan-Meier analysis was 9·8 years (95% CI 8·1-11·4). The parkinsonian variant of MSA (hazard ratio [HR] 2·08, 95% CI 1·09-3·97; p=0·026) and incomplete bladder emptying (HR 2·10, 1·02-4·30; p=0·044) predicted shorter survival. 24-month progression rates of UMSARS activities of daily living, motor examination, and total scores were 49% (9·4 [SD 5·9]), 74% (12·9 [8·5]), and 57% (21·9 [11·9]), respectively, relative to baseline scores. Autonomic symptom scores progressed throughout the follow-up. Shorter symptom duration at baseline (OR 0·68, 0·5-0·9; p=0·006) and absent levodopa response (OR 3·4, 1·1-10·2; p=0·03) predicted rapid UMSARS progression. Sample size estimation showed that an interventional trial with 258 patients (129 per group) would be able to detect a 30% effect size in 1-year UMSARS motor examination decline rates at 80% power. Our prospective dataset provides new insights into the evolution of MSA based on a follow-up period that exceeds that of previous studies. It also represents a useful resource for patient counselling and planning of multicentre trials.

4 October 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MKMartin Köllensperger
Martin Köllensperger
FGFelix Geser
Felix Geser
JNJean‐Pierre Ndayisaba
Jean‐Pierre Ndayisaba
SBSylvia Boesch
Sylvia Boesch
KSKlaus Seppi
Klaus Seppi
OEOn Behalf Of The Emsa‐Sg
On Behalf Of The Emsa‐Sg

28 April 2008 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MKMartin Köllensperger
Martin Köllensperger
FGFelix Geser
Felix Geser
KSKlaus Seppi
Klaus Seppi
MSMichaela Stampfer‐Kountchev
Michaela Stampfer‐Kountchev
MSMartin Sawires
Martin Sawires
GWGregor K. Wenning
Gregor K. Wenning

15 June 2013 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
AAAlberto Albanese
Alberto Albanese
FSFRANCESCA DEL SORBO
FRANCESCA DEL SORBO
CCCynthia Comella
Cynthia Comella
HJH. A. Jinnah
H. A. Jinnah
JMJonathan W. Mink
Jonathan W. Mink
ASAnette Schrag
Anette Schrag

7 July 2020 in Brain
Verified
Journal Article
Open access
PDF file
Roberto CiliaRoberto Cilia
Roberto Cilia
ECEmanuele Cereda
Emanuele Cereda
AAAlbert Akpalu
Albert Akpalu
FSFred Stephen Sarfo
Fred Stephen Sarfo
MCMomodou Cham
Momodou Cham
GPGianni Pezzoli
Gianni Pezzoli
The natural pattern of progression of Parkinson’s disease is largely unknown because patients are conventionally followed on treatment. As Parkinson’s disease progresses, the true magnitude of the long-duration response to levodopa remains unknown, because it can only be estimated indirectly in treated patients. We aimed to describe the natural course of motor symptoms by assessing the natural OFF in consecutive Parkinson’s disease patients never exposed to treatment (drug-naïve), and to investigate the effects of daily levodopa on the progression of motor disability in the OFF medication state over a 2-year period. In this prospective naturalistic study in sub-Saharan Africa, 30 Parkinson’s disease patients (age at onset 58 ± 14 years, disease duration 7 ± 4 years) began levodopa monotherapy and were prospectively assessed using the Unified Parkinson’s disease Rating Scale (UPDRS). Data were collected at baseline, at 1-year and 2-years follow-up. First-ever levodopa intake induced a significant improvement in motor symptoms (natural OFF versus ON state UPDRS-III 41.9 ± 15.9 versus 26.8 ± 15.1, respectively; P < 0.001). At 1-year follow-up, OFF state UPDRS-III score after overnight withdrawal of levodopa was considerably lower than natural OFF (26.5 ± 14.9; P < 0 .001). This effect was not modified by disease duration. At the 2-year follow-up, motor signs after overnight OFF (30.2 ± 14.2) were still 30% milder than natural OFF (P = 0.001). The ON state UPDRS-III at the first-ever levodopa challenge was similar to the overnight OFF score at 1-year follow-up and the two conditions were correlated (r = 0.72, P < 0.001). Compared to the natural progression of motor disability, levodopa treatment resulted in a 31% lower annual decline in UPDRS-III scores in the OFF state (3.33 versus 2.30 points/year) with a lower model’s variance explained by disease duration (67% versus 36%). Using the equation regressed on pretreatment data, we predicted the natural OFF at 1-year and 2-year follow-up visits and estimated that the magnitude of the long-duration response to levodopa ranged between 60% and 65% of total motor benefit provided by levodopa, independently of disease duration (P = 0.13). Although levodopa therapy was associated with motor fluctuations, overnight OFF disability during levodopa was invariably less severe than the natural course of the disease, independently of disease duration. The same applies to the yearly decline in UPDRS-III scores in the OFF state. Further research is needed to clarify the mechanisms underlying the long-duration response to levodopa in Parkinson’s disease. Understanding the natural course of Parkinson’s disease and the long-duration response to levodopa may help to develop therapeutic strategies increasing its magnitude to improve patient quality of life and to better interpret the outcome of randomized clinical trials on disease-modifying therapies that still rely on the overnight OFF to define Parkinson’s disease progression.

8 June 2012 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MGMDS-UPDRS Italian Validation Study Group
MDS-UPDRS Italian Validation Study Group
Angelo AntoniniAngelo Antonini
Angelo Antonini
GAGiovanni Abbruzzese
Giovanni Abbruzzese
LSLuigi Ferini Strambi
Luigi Ferini Strambi
BTBarbara Tilley
Barbara Tilley
FSFRANCESCA DEL SORBO
FRANCESCA DEL SORBO